Eli Lilly and Company ( NYSE:LLY ) defied analyst predictions to release its quarterly results, which were ahead ...

Wall Street rallied higher as investors digested upbeat earnings from big tech companies during the week. The Nasdaq gained 2 ...

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...

Discover how potential U.S. price cuts on obesity drugs could impact LLY and NVO revenues, stock sentiment, and valuation ...

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...

Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...

Drug company Eli Lilly and NVIDIA announced a new partnership to build a supercomputer for drug research. Drug manufacturer ...